[go: up one dir, main page]

IL201897A0 - Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies - Google Patents

Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies

Info

Publication number
IL201897A0
IL201897A0 IL201897A IL20189709A IL201897A0 IL 201897 A0 IL201897 A0 IL 201897A0 IL 201897 A IL201897 A IL 201897A IL 20189709 A IL20189709 A IL 20189709A IL 201897 A0 IL201897 A0 IL 201897A0
Authority
IL
Israel
Prior art keywords
spla2
dyslipidemia
inhibitors
treatment
cardiovascular disease
Prior art date
Application number
IL201897A
Original Assignee
Anthera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2008/062577 external-priority patent/WO2008137803A1/en
Application filed by Anthera Pharmaceuticals Inc filed Critical Anthera Pharmaceuticals Inc
Publication of IL201897A0 publication Critical patent/IL201897A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL201897A 2007-05-03 2009-11-03 Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies IL201897A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91591007P 2007-05-03 2007-05-03
US96959107P 2007-08-31 2007-08-31
US19004407P 2007-10-18 2007-10-18
PCT/US2008/062577 WO2008137803A1 (en) 2007-05-03 2008-05-02 Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies

Publications (1)

Publication Number Publication Date
IL201897A0 true IL201897A0 (en) 2010-06-16

Family

ID=42263481

Family Applications (1)

Application Number Title Priority Date Filing Date
IL201897A IL201897A0 (en) 2007-05-03 2009-11-03 Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies

Country Status (3)

Country Link
KR (1) KR20100109840A (en)
IL (1) IL201897A0 (en)
MX (1) MX2009011925A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250014832A (en) * 2023-07-21 2025-02-03 현대약품 주식회사 Pharmaceutical composition and its preparation method

Also Published As

Publication number Publication date
MX2009011925A (en) 2010-06-25
KR20100109840A (en) 2010-10-11

Similar Documents

Publication Publication Date Title
HUS2100020I1 (en) Bi-aryl meta-pyrimidine inhibitors of kinases
SI2389352T1 (en) Arginase inhibitors and methods of use
IL208719A0 (en) Inhibitors of protein kinases
EP2026843A4 (en) Therapeutic uses of inhibitors of rtp801l
IL210363A0 (en) Kinase inhibitors and methods of use
EP2252293A4 (en) Kinase inhibitors and methods of use
PL2101759T3 (en) Methods of using mek inhibitors
IL240771A0 (en) Benzoxazole kinase inhibitors and methods of use
SI2038265T1 (en) Human protein-tyrosine phosphatase inhibitors and methods of use
IL200611A0 (en) Inhibitors of serine proteases
IL208212A0 (en) Hydroxamate-based inhibitors of deacetylases b
ZA201006353B (en) Inhibitors of gm-csf and il-17 for therapy
ZA200804083B (en) Bi-aryl meta-pyrimidine inhibitors of kinases
IL201254A0 (en) 5 - oxo - isoxazoles as inhibitors of lipases and phospholipases
EP2154958A4 (en) Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies
IL201897A0 (en) Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies
HK1139282A (en) Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies
IL212990A0 (en) Treatment of major adverse cardiac events and acute coronary syndrome using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies
GB0816143D0 (en) Frequency reference devices and methods of providing frequency references
HK1152890A (en) Inhibitors of gm-csf and il-17 for therapy
IL195722A0 (en) Therapeutic uses of inhibitors of rtp801l
HK1146059A (en) Hydroxamate-based inhibitors of deacetylases b
GB0621103D0 (en) Inhibitors of MEK